HIV-specific CD8+ T-cells derived from autologous peripheral blood mononuclear cells (NIAID)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHIV-specific CD8+ T-cells derived from autologous peripheral blood mononuclear cells (NIAID)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunomodulatorsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A